NHS Access to Weight Loss Drug Mounjaro Marked by Postcode Lottery

Access to the weight loss drug Mounjaro is being unevenly distributed across England, creating a “postcode lottery” for patients, according to a recent investigation. Despite national guidelines recommending Mounjaro for individuals with a body mass index (BMI) over 35 and at least one weight-related health condition, Integrated Care Boards (ICBs) are implementing stricter criteria to manage costs, leading to disparities in access.

National Guidelines and Local Restrictions

National Institute for Health and Care Excellence (NICE) recommends tirzepatide (Mounjaro®) for the management of obesity for certain patients. NHS England guidelines state that GPs should prescribe Mounjaro to those with a BMI over 40 and four or more weight-related conditions, such as high blood pressure, heart disease, and type 2 diabetes. However, some ICBs are imposing more stringent requirements.

These restrictions mean that patients who could access the drug with an NHS prescription if they lived in a different area are being denied treatment. Individuals are either going without the medication or are forced to pay approximately £200 per month for private prescriptions.

Variations in ICB Criteria

An analysis by trade publication The Pharmacist revealed significant differences in ICB policies. Some ICBs exclude patients with unstable mental illness or a history of eating disorders. Others prioritize individuals from deprived areas, while one ICB requires patients to demonstrate prior attempts at weight loss before considering prescribing the drug.

Greater Manchester ICB has implemented a tiered system within the first cohort of eligible patients, prioritizing those with the most pressing clinical needs.

NHS Rollout and Funding Concerns

While Health Secretary Wes Streeting has described Mounjaro as a “game-changer” and pledged to increase access, the NHS has implemented a phased 12-year rollout plan. The BBC reports that only 220,000 patients will be prioritized in the first three years. Later cohorts will have access with lower BMI thresholds and fewer co-morbidities.

NHS spending on Mounjaro has increased by up to 200% since GPs were first authorized to prescribe it eight months ago. However, spending varies considerably across ICBs, with North East and North Cumbria ICB spending the most (£16.8 million from April to November 2025) and Dorset ICB spending the least (£1.1 million).

Financial Incentives for GPs

The new GP contract, effective from April, introduces bonuses for family doctors who prescribe weight loss jabs to obese patients and refer others to weight management classes. MSN reports that a typical GP practice could receive an extra £3,000 annually by prescribing Mounjaro to at least 80% of eligible patients.

However, Dr. Katie Bramall, chair of the British Medical Association’s GP committee, expressed concern that these proposals will not address the existing inequalities in access, leaving those unable to afford private treatment waiting.

Mounjaro: Efficacy and Considerations

Mounjaro, also known as tirzepatide, has demonstrated significant efficacy in weight loss, with studies showing patients can lose up to a fifth of their body weight within a little over a year. The Daily Mail reports that the drug is sometimes referred to as the “King Kong” of weight loss drugs.

It’s important to note that Mounjaro is an injection taken once weekly and works by making individuals perceive fuller for longer, reducing hunger. Healthcare professionals will discuss the benefits and potential side effects before prescribing the medication. A balanced diet and regular physical activity are essential components of treatment.